Company:Synthaverse S.A.
| File:210px | |
| Type | Spółka Akcyjna |
|---|---|
| Template:WSE | |
| Industry | Biotechnology, Pharmaceutical |
| Founded | 1944 |
| Headquarters | Lublin, Poland |
Key people | Piotr Fic (interim CEO) Jarosław Błaszczak (Chairman of the Supervisory Board) |
Number of employees | 230 (2019)[1] |
| Website | https://synthaverse.com/pl/ |
Synthaverse S.A., formerly known as Biomed-Lublin Wytwórnia Surowic i Szczepionek (Biomed-Lublin Serum and Vaccine Production Plant) is a Polish pharmaceutical company operating since 1944. The company manufactures medicinal preparations (prescription drugs, medical devices and laboratory reagents used in biochemical and medical laboratories). The company's headquarters is in Lublin, (Poland).
History
The history of the company go back to 1944, when the Laboratory for the Production of Vaccines against Typhus was opened at the National Institute of Hygiene in Lublin (later the Rudolf Weigl production facility of vaccine against typhus), and shortly after that, the Serum and Vaccines factory. Initially, vaccines against rabies, dysentery and typhoid, and Delbet's nonspecific stimulative vaccine, anti-diphtheritic and antitetanic sera. In 1951, both plants merged to form Lubelska Wytwórnia Surowic i Szczepionek. In the years 1951–1960, the company significantly developed, increased employment, expanded its production departments and expanded its product range.[2]
In 1976, the plant was reorganized: four production departments were established: the Faculty of Vaccines, Chemistry and Auxiliary Production, the Faculty of Virology, the Faculty of Serum and Laboratory Animals, the Faculty of Protein Fractions and Organopreparations. As a result of these activities, the company started introducing new technologies, modernizing devices and expanding the product range.
Currently, the company deals with the production of medicinal preparations, medical devices and laboratory reagents (used in biochemical and medical laboratories).[citation needed]
In August 2020, Biomed-Lublin started the production of anti-SARS-CoV-2 immunoglobulin from the plasma of convalescents for the purposes of clinical trials.[3][4] On September 23, the first stage of production of this preparation was completed.[5]
In July 2023, Biomed-Lublin officially rebranded to Synthaverse S.A. to reflect its new strategic direction, which includes combining different scientific ideas and approaches to develop pharmaceutical technologies.
Products
- BCG vaccine (contains the Brazilian substrain M. bovis BCG Moreau) [6][7]
- Biotrombina
- Onko BCG
- Gastrotrombina
- Distreptaza
- Histaglobulina
- Gamma anty-D
- Gamma anty HBs
- Lakcid
References
- ↑ "Company Information". https://www.bankier.pl/gielda/notowania/akcje/BIOMEDLUB/wladze-zatrudnienie.
- ↑ "Biomed-Lublin History". https://biomedlublin.com/en/kim-jestesmy/#historia.
- ↑ "Poland's Biomed Lublin may be first to offer Covid-19 plasma-based drug". 4 August 2020. https://emerging-europe.com/news/polands-biomed-lublin-may-be-first-to-offer-covid-19-plasma-based-drug/.
- ↑ "In World First, Polish Pharmaceutical Company Produces Plasma-Derived COVID Drug". 18 August 2020. https://theglobepost.com/2020/08/18/poland-covid-19-drug/.
- ↑ "Biomed Lublin: drug for COVID-19 goes into ampoules". 23 September 2020. https://healthcaremarketexperts.com/en/news/coronavirus/biomed-lublin-drug-for-covid-19-goes-into-ampoules/.
- ↑ "Biomed Lublin Products". biomedlublin.com. https://biomedlublin.com/en/produkty/#leki.
- ↑ "Poland among last countries in Europe still recommending universal BCG vaccination". pzh.gov.pl. https://szczepienia.pzh.gov.pl/en/stories/poland-is-among-the-last-countries-in-europe-still-recommending-universal-bcg-vaccination/.
External links
 |  |
